We constructed a series of adenoviral (Ad) vectors that express the Candida albicans cytosine deaminase (CD) suicide gene under the transcriptional control of either the human ␣-lactalbumin (ALA) or ovine ␤-lactoglobulin (BLG) promoter (Ad.ALA.CD and Ad.BLG.CD, respectively). The Ad.ALA.CD and the Ad.BLG.CD vectors converted the prodrug 5-fluorocytosine (5-FC) to the toxic nucleotide analog 5-fluorouracil in a breast cancer cell-specific manner, with a conversion rate of 40% and 52% in T47D cells and 50% and 41% in MCF7 cells, respectively. No significant conversion (Յ3%) was observed in an immortalized nontumorigenic breast epithelial cell line (MCF10A) and a human osteosarcoma cell line (U2OS). Adenovirus vector-based prodrug conversion of the 5-FC in T47D and MCF7 in the presence of 1 mg/mL of 5-FC led to cytotoxicity that resulted in a nearly complete cell death (Ն90%) after 5 days, whereas MCF10A and U2OS cells remained resistant (Յ10%). Nude mice harboring T47D-derived breast tumors that were injected intratumorally (i.t.) with therapeutic adenovirus vectors at a dose of 2 ϫ 10 8 plaque-forming units and treated systemically with 5-FC at a concentration of 500 mg/kg/day showed a marked reduction in tumor mass within 30 days when compared with animals that received vector alone. Animal survival was significantly prolonged after 72 days in mice treated with therapeutic vectors in conjunction with prodrug when compared with control animals. These preclinical data are sufficiently promising to warrant further studies of this transcriptional targeting approach to breast cancer treatment.
fforts to improve the specificity of all treatment modalities continue to be a major focus of cancer research. In gene therapy, several approaches have attempted to address this problem of treatment specificity. 1 Our group previously described the use of a transcriptional targeting strategy to enable the specific expression of genes in breast cancer cells. 2 In our initial studies, we used promoters of the human ␣-lactalbumin (ALA) gene and the ovine ␤-lactoglobulin (BLG) gene to drive breast cancer-specific expression of the herpes simplex virus thymidine kinase (HSV-tk) suicide gene. 2 Because cancer treatment often requires combinations of therapy to be effective, we have extended this prior work to generate breast cancer-specific vectors containing the ALA and BLG promoters driving the expression of the Candida albicans cytosine deaminase (CD) suicide gene.
The CD gene is normally expressed in bacterial or fungal organisms and functions in the purine biosynthesis pathway to deaminate cytosine to uracil. 3 The product of the CD gene has also been shown by others to metabolize the prodrug 5-fluorocytosine (5-FC) to the toxic nucleotide analog 5-fluorouracil (5-FU). 4 Although 5-FC is nontoxic in cells even at high concentrations, the activated analog is extremely toxic to human cells at low concentrations. 4 In fact, the analog 5-FU has been widely incorporated into chemotherapeutic treatment modalities for various types of cancer. 5 Others have shown that transfer of the CD gene into neoplastic cells results in selective sensitivity to the prodrug 5-FC, whereas normal and untransduced cells remain resistant to prodrug. 4 In one recent report, the CD gene was employed to render colorectal carcinomas susceptible to 5-FC with promising results. 6 This study, which employed 5-FC concentrations as high as 500 mg/kg/day in treated animals, reported positive effects with no cytotoxicity at the administered prodrug dosage in phase I clinical trials.
An enhanced bystander effect has also been attributed to the use of the CD/5-FC suicide gene system when compared with the HSV-tk/ganciclovir (GCV) system. This is presumably due to the fact that uptake of 5-FC is more efficient than uptake of GCV. Moreover, converted 5-FC is able to freely diffuse from one initially transduced cell to surrounding cells, which negates the need for gap junction-mediated transfer. Because only 10 -25% on average of the tumor mass may be transduced with vector in an in vivo gene therapy approach, the diffusion of activated prodrug provides the advantage of allowing activated 5-FC to disseminate to untransduced tumor cells within the population that are not in direct contact with transduced cells.
In this paper, we describe the successful results of two recombinant adenoviral (Ad) vectors containing tumortargeting expression cassettes of either the ALA or BLG promoters driving the C. albicans CD gene (Ad.ALA.CD and Ad.BLG.CD), when these vectors were used to transduce breast cancer cells in vitro. Moreover, breast cancer cells infected with these vectors exhibit selective sensitization to prodrug when compared with immortalized nontumorigenic breast cells or nonbreast cancer cells in vitro. We also report a correlation of estrogen receptor (ER) positivity and expression levels from these promoters in breast cancer cell lines with altered ER status when these cell lines were transduced with tumor cell-specific reporter adenovectors (Ad.ALA.␤-gal and Ad.BLG.␤-gal). Nude mice studies with T47D human breast tumors demonstrated a tumor regression profile when animals were injected with tumor-selective adenovectors in conjunction with prodrug. Furthermore, survival was prolonged in animals treated with both vector and prodrug compared with control animals. These results, which show that the tissue-specific expression of CD in breast tumors in nude mice is effective in tumor eradication, warrant further studies of this transcriptional targeting approach to breast cancer treatment.
MATERIALS AND METHODS

Cell lines
The human breast carcinoma cell lines cell lines T47D, MCF7, and ZR75-1, the human osteosarcoma cell line U2OS, and the nontransformed human breast epithelial cell line MCF10A were described in our previous report. 2 The cell line ZR75-30 was obtained from the American Type Culture Collection (Manassas, Va). The cell lines T47D/C42, MCF7/5C, and MD-MBA231/S30 were kindly provided by Dr Craig Jordan (Northwestern University) and are either estrogen-unresponsive (MCF7/5C), 8 lack the ER (T47D/C42), 9 or are stably transfected with the full-length human ER (MD-MBA231/ S30). 10 These three cell lines were grown in their respective modified media: T47D/C42 and MCF7/5C, RPMI 1640 without phenol red, 10% charcoal-stripped fetal calf serum, and 0.2 international units of bovine insulin/mL; MD-MBA231/S30, minimum essential medium without phenol red, 10% charcoalstripped fetal calf serum, 0.2 international units of bovine insulin/mL, and 500 g/mL G418.
Adenovirus vectors
Construction of the replication-defective adenovirus vector expressing ␤-galactosidase (␤-gal) from cytomegalovirus (CMV) (Ad.CMV.␤-gal), ALA (Ad.ALA.␤-gal), and BLG (Ad.BLG.␤-gal) promoters in the E1A region have been described in detail in our previous report. 2 The replicationdefective adenovirus vectors expressing CD gene from the CMV promoter (Ad.CMV.CD), the ALA promoter (Ad.ALA.CD), and the BLG promoter (Ad.BLG.CD) were constructed exactly as described previously. 2, 11 In brief, the coding sequences of the ␤-gal gene from the adenovirus transfer plasmids expressing ␤-gal from CMV, ALA, and BLG promoters 2 were substituted with coding sequences of the CD gene from a plasmid containing cDNA sequences for the CD gene 6 (a gift from Dr. Ron Crystal, Weill Medical College of Cornell University, New York, NY). All clones were confirmed by sequencing DNA. The virus isolates were plaque purified on human 293 cells at least twice before use.
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Reporter assays of breast cancer cell lines Cell lines were infected with either Ad.CMV.␤-gal, Ad.ALA.␤-gal, or Ad.BLG.␤-gal or were mock-infected (phosphate-buffered saline (PBS)) at 20 plaque-forming units (PFU)/cell on 60-mm plates when cells were at ϳ80% confluence. After a 1-hour incubation period, virus was aspirated; medium was added and was allowed to incubate for 48 hours at 37°C in 5% CO 2 . Cell lysates were then harvested in 1ϫ lysis buffer (diluted from 5ϫ stock concentration; 5ϫ lysis buffer; Promega, Madison, Wis) and subjected to three cycles of freeze/thawing. Cells debris was cleared by centrifugation at 2000 ϫ g for 5 minutes, and the resulting supernatant was isolated and quantitated for total protein concentration using the Bradford method. 12 Aliquots of cell lysate were subjected to a ␤-gal chemiluminescence assay (Clontech, Palo Alto, Calif) for ␤-gal activity using a 96-well plate reader; absorbance was measured at 520 nm according to the manufacturer's recommendations. Data are expressed as mean ␤-gal relative light units per microgram of protein Ϯ SEM versus the cell line assayed. Each experiment was measure in triplicate and performed at least three times.
CD-mediated prodrug conversion assay in vitro
Various cell lines were infected with either Ad.CMV.CD, Ad.ALA.CD, Ad.BLG.CD, or Ad.CMV.␤-gal at 20 PFU/cell on 60-mm plates when cells were at ϳ80% confluence; next, cells were allowed to incubate for 48 hours at 37°C in 5% CO 2 . Cells were then harvested and subjected to three cycles of freeze/thawing in lysis buffer containing 100 mM tris(hydroxymethyl)aminomethane (pH 7.8), 1 mM ethylenediaminetetraacetic acid, and 1 mM dithiothreitol. An aliquot of lysate (100 g) was then incubated with 22. 
Prodrug-mediated cytotoxicity assay in vitro
Various cell lines were infected with either Ad.CMV.CD, Ad.ALA.CD, Ad.BLG.CD, or Ad.CMV.␤-gal at 20 PFU/cell on 60-mm plates and reincubated at 37°C. After 24 hours, infected cells were harvested and plated at a density of 5000 cells/well in 96-well plates in which fresh medium containing various concentrations (0.1-1000 g/mL) of 5-FC (Sigma, St. Louis, Mo) had been added. Medium was removed every 24 hours, and fresh medium containing 5-FC was added. After 5 days, cell proliferation and viability were measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay (Promega). Data are expressed as the percentage of viable cells versus 5-FC concentration Ϯ SEM. All experiments were done in triplicate and performed at least twice.
Tumor models and 5-FC treatment T47D cell xenografts were raised in estrogen implanted 4-to 6-week-old female BALB/c nu/nu athymic mice exactly as described previously. 2 Tumors were allowed to grow for 2 weeks before randomizing mice by tumor size. All tumors were at least 100 mm 3 , and mice were grouped according to treatment regimen (i.e., virus ϩ 5-FC, virus ϩ 0.9% NaCl). Mice then received a single i.t./peritumoral injection of a control or CD virus (2 ϫ 10 8 PFU in 100 L of 0.9%NaCl). At 24 hours postinjection, mice received either 5-FC (500 mg/kg/ day) or vehicle (0.9% NaCl) intraperitoneally (i.p.) daily for a total of 3 weeks. Mice were monitored for tumor size daily by measuring the tumor with Vernier calipers. Volumes were calculated using the following formula: L ϫ W 2 ϫ 0.5, where L is the length and W is the width of the tumor. Mice were sacrificed if they appeared moribund or unable to feed due to tumor burden; this was recorded as the date of expiration. Because tumor sizes are randomized, the initial measurements taken at day 0 before prodrug treatment were given a value of 1.0. All subsequent measurements are a percentage of this value. The values plotted are the mean value (n ϭ 5) of mouse tumors in each treatment group.
RESULTS
Effect of the ER on ALA and BLG expression levels in vitro
We have previously demonstrated ALA and BLG tissue specificity in breast cancer cells both in vitro and in vivo. 2 However, because estrogen is normally involved in breast cell growth and differentiation during lactogenesis, 13 and because nearly 30% of breast tumors are ER Ϫ , we wanted to determine whether the activation of the two breast tissue-specific promoters used in this study is dependent upon ER. Human breast cell ER variants were transduced with either Ad.ALA.␤-gal, Ad.BLG.␤-gal, Ad.CMV.␤-gal or were mock-infected (PBS) to determine whether the presence of a functional ER is involved in the transcriptional regulation of the ALA and BLG promoters in human breast cancer cells. The cell lines MCF7/5C 8 and T47D/C42, 9 which are either ER Ϫ (T47D/C42) or lack a functional receptor (MCF7/ 5C), and MD-MBA231/S30, 10 which contains a stably transfected full-length ER, were infected at 20 PFU/cell with either Ad.ALA.␤-gal, Ad.BLG.␤-gal, Ad.CMV.␤-gal or were mock-infected (PBS) and assayed for ␤-gal activity using a chemiluminescence reporter system. Experiments using the parental T47D (ER Prodrug conversion and cytotoxicity of CD-containing adenovectors in vitro Prodrug conversion assays were conducted to assess the efficiency of conversion of 5-FC to the active metabolite 5-FU via the ALA and BLG promoters in T47D (Fig  2A) , MCF7 (Fig 2B), MCF10A (Fig 2C) , and U2OS (Fig 2D) , and MD-MDA231/S30 (ER ϩ ; derived by stably transfecting MD-MDA231 with functional ER) were infected with Ad.ALA.␤-gal, infected with Ad.BLG.␤-gal, or mock-infected at 20 PFU/cell. Cells were harvested and lysed after 48 hours, and equal quantities of protein from these cell lysates were assayed for ␤-gal activity using a chemiluminescence kit (Clontech). All measurements were done in triplicate and performed at least twice.
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the positive control Ad.CMV.CD displayed a timedependent prodrug conversion profile, with maximal conversion after 4 hours within the range of 74.4 -96.2%. This indicates that cells transduced with adenovector containing the CMV-driven CD gene gained the neomorphic ability to deaminate 5-FC to 5-FU. However, only the breast cancer cell lines T47D and MCF7, transduced with Ad.ALA.CD or Ad.BLG.CD, were able to convert prodrug at 40% and 52% (T47D) and 50% and 41% (MCF7), respectively, after 4 hours when compared with the immortalized, but otherwise normal, MCF10A or human osteosarcoma U2OS cells (3% conversion). No significant conversion was observed in cells that were transduced with the reporter vector Ad.CMV.␤-gal (1% conversion). These results indicate that T47D and MCF7 human breast cancer cells transduced with our breast tumor-specific adenovectors Ad.ALA.CD or Ad.BLG.CD acquired the selective ability to convert the prodrug 5-FC to 5-FU when compared with control adenovectors.
To determine whether the expression levels and subsequent prodrug conversion percentages in Ad.ALA.CD-and Ad.BLG.CD-transduced cells were sufficient to render cells sensitive to 5-FC-mediated cell killing, we infected T47D, MCF7, MCF10A, and U2OS cells with either Ad.ALA.CD, Ad.BLG.CD, Ad.CMV.CD, or Ad.CMV.␤-gal at 20 PFU/cell and subjected all cells to various 5-FC concentrations (0.1-1000 g/mL). After a period of 5 days, all cells were assayed for cell viability and proliferation using the MTT assay. Figure 3 shows that all cells that were transduced with the positive control vector Ad.CMV.CD displayed a sensitivity to 5-FC in a dose-dependent manner. This indicates that all of the cell lines assayed were able to display sensitivity to 5-FC-mediated cell killing after transduction of the vector containing a constitutively active CD gene (Ad.CMV.CD). However, only the T47D and MCF7 breast cancer cells displayed sensitivity to prodrug-mediated cell killing in a dosedependent manner comparable with cells infected with Ad.CMV.CD. MCF10A breast cells and U2OS cells were relatively resistant to prodrug-mediated cell killing despite being transduced with Ad.ALA.CD or Ad.BLG.CD. All cells remained resistant to 5-FCmediated cell killing when transduced with the negative control Ad.CMV.␤-gal. These results demonstrate that Ad.ALA.CD and Ad.BLG.CD are able to selectively render T47D and MCF7 breast cancer cells sensitive to prodrug-mediated cell killing in a dosedependent manner.
Therapeutic efficacy of Ad.CD vectors in human breast tumor xenografts and animal survival
To determine the sensitivity of breast cancer cells transduced with the CD gene in vivo, nude mice harboring T47D-derived human breast xenografts subcutaneously over the mammary fat pad 2 were divided into random subgroups (n ϭ 10) and injected i.t. with 2 ϫ 10 8 PFU of either Ad.ALA.CD, Ad.BLG.CD, Ad.CMV.CD, or Ad.CMV.␤-gal. After 24 hours, mice were subdivided into smaller groups (n ϭ 5) in which a subset received either 5-FC at 500/mg/kg/day or saline (0.9% NaCl) by i.p. injections daily for a period of 21 days. Tumor volume was measured every 2 days and was calculated as a percentage of the original volume before prodrug treatment. Animals that received the therapeutic vector Ad.CMV.CD and prodrug displayed a marked regression in tumor volume (Fig 4) during the first 30 days, with maximal regression within the first month of treatment. Likewise, animals that received either Ad.ALA.CD or Ad.BLG.CD and prodrug had in a tumor regression profile that was similar to that seen for the positive control. However, no significant amount of regression was observed when animals received therapeutic vector plus saline or the negative control vector (Ad.CMV.␤-gal) and prodrug or saline. Figure 5 shows that animals undergoing treatment with both therapeutic vector plus prodrug experienced prolonged survival during the treatment and monitoring period of 72 days. Treatment groups that received either Ad.ALA.CD or Ad.BLG.CD plus 5-FC experienced an overall survival percentage of 60% and 80%, respectively. However, none of the animals that received therapeutic vector plus saline or reporter vector survived after 49 days. These results indicate that the CD expression levels from the Ad.ALA.CD and Ad.BLG.CD therapeutic vectors were sufficient to cause marked tumor regression, in conjunction with the prodrug 5-FC, and prolonged animal survival when compared with control animals. Moreover, both therapeutic vector and prodrug are required for any significant regression and subsequent prolonged survival to occur when compared with animals that received either therapeutic vector plus saline or reporter vector plus prodrug.
DISCUSSION
Targeted gene therapy for cancer provides much potential for novel and effective modalities that use molecular characteristics specific to tumor cells. In a previous study, we demonstrated that ALA-or BLG-driven HSV-tk gene expression, in the presence of the prodrug GCV, resulted in a marked reduction in human breast cancer tumors in nude mice. 2 We have now extended this work to the CD suicide gene and have shown that adenovirus vectors harboring either the ALA or the BLG promoter-driven CD gene in the presence of the prodrug 5-FC are very effective in regressing the human breast tumors raised in nude mice.
Because estrogen is normally involved in breast cell growth and differentiation during lactogenesis, 13 and because a significant percentage of breast cancer cases are ER Ϫ , we wanted to determine whether our tissuespecific promoter-based therapeutic strategy would be applicable to ER Ϫ breast tumors. The data presented in Figure 1 suggest that a positive correlation exists between the ER and expression from ALA and BLG. When the ER is nonfunctional or not present, we consistently observed reduced expression of the reporter gene ␤-gal from our breast-specific promoters. These data are in agreement with pathological observations that indicate that very few ALA-positive breast tumors are also ER Ϫ . 14 In our experiments, the absence of the ER only results in half-maximal expression, which suggests that other factors that are estrogen-independent are involved in normal levels of expression. Conversely, addition of the full-length ER cDNA in ER Ϫ MD-MDA231 cells resulted in increased levels of expression. This suggests a potential strategy to increase responsiveness of ER Ϫ breast tumor cells to ALA-or BLGmediated gene therapy by incorporating an expression cassette containing the full-length ER into a vector under the transcriptional control of either ALA or BLG. Administration of this vector would result in an autocrine system in which expression of the ER would lead to increased levels of therapeutic gene expression.
We observed tissue-specific prodrug conversion and cytotoxicity when T47D and MCF7 breast cancer cells were transduced with Ad.ALA.CD or Ad.BLG.CD. Although the percentage of prodrug conversion to toxic metabolite in breast cancer cells was approximately half that of Ad.CMV.CD-mediated prodrug conversion, we observed similar amounts of cell killing. Perhaps the expression levels of CD from ALA and BLG meet some threshold requirement for maximal cell killing and a high level of expression of CD from the CMV promoter is not needed. Others have reported a minimal threshold level requirement in which they observed no significant difference in cell killing when comparing HSV-tk expression levels from the CMV and Rous sarcoma virus promoters. 15 No significant cell killing was observed when either U2OS or MCF10A cells were transduced with our tissue-specific adenovectors at prodrug concentrations as high as 1000 g/mL, suggesting that these promoters exhibit a remarkable breast tumor specificity when compared with the nontumorigenic MCF10A cells. The ability of these promoters to selectively render breast tumor cells, but not normal breast cells, sensitive to prodrug-mediated cell killing provides another level of specificity when considering targeting tumors within the normal breast tissue.
Nude mouse tumor regression was observed only in mice receiving both therapeutic vector and prodrug. Mice that received Ad.CMV.CD and 5-FC exhibited marked tumor regression during the first 30 days of treatment. Likewise, animals that received Ad.ALA.CD or Ad.BLG.CD exhibited regression profiles that were similar to the positive control. Animals that received either therapeutic vector plus saline or reporter vector displayed no signs of regression. Although the onset of regrowth occurred after 30 days, tumors in treated animals were significantly smaller than those seen in control animals even after a period of 45 days. In these experiments, treated animals displayed a rapid decrease in tumor mass during prodrug treatment; this decrease began to subside after the third week of prodrug administration. Perhaps the initial regression observed was due to eradication of the transduced cell population, while subsequent regression may be due to a 5-FU-mediated bystander effect of untransduced cells within the tumor mass. Others have reported a bystander effect in solid tumors undergoing CD-based gene therapy. 16 Because 5-FU is able to freely diffuse to surrounding cells, a potent bystander effect is normally observed that results in a greater percentage of tumor regression. In our experiments, survival was significantly prolonged when animals were treated with therapeutic vector in conjunction with 5-FC after 45 days. Control animal survival was significantly reduced due to progressive cancer and increased tumor growth. The decreased survival in control animals was probably not due to prodrug concentration, because others have reported using prodrug doses in this range without cytotoxicity.
In summary, we demonstrate a potentially effective strategy to target expression of the C. albicans CD gene to breast cancer cells both in vitro and in vivo. This strategy uses the normally lactation-inducible promoters ALA and BLG, because a large percentage of clinical breast cancer specimens are positive for ALA. Moreover, we report a correlation between the ER and the transcriptional activation/regulation of the ALA and BLG promoter sequences in reporter assays conducted in breast cell ER variants. The expression levels of CD from the ALA and BLG promoters are sufficient to selectively render breast tumor cells sensitive to 5-FC in cytotoxicity assays. Human breast tumors in nude mice displayed marked regression when treated with tumor-specific adenovector and prodrug. Moreover, survival was significantly prolonged when animals were treated with both therapeutic vector and prodrug. These observations and our previous report showing that transcriptionally targeted tk gene into breast tumors is effective in tumor regression in a nude mouse model raise the possibility of a combined therapy in which two suicide genes can be delivered to breast cancer cells in a tissuespecific manner. Further, these observations are sufficiently promising to warrant further studies of this transcriptional targeting approach to breast cancer treatment.
